Drugs and Valvular Heart Disease
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
In 1997, Connolly et al. reported that both racemic fenfluramine (Pondimin) and dexfenfluramine (Redux) were associated with valvular heart disease.1 The valvular abnormalities seen in patients treated with these agents were distinctive. On echocardiography, leaflet thickening as well as chordal thickening and retraction were observed. Surgically removed valves were noted to have a glistening white surface, with histologic evidence of a plaque-like process extending along the leaflet surfaces and encasing the chordae tendineae. These findings were similar to those in patients with heart-valve damage induced by serotonin-secreting carcinoid tumors.1 This association of racemic fenfluramine and dexfenfluramine with valvular heart disease . . .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, valvular heart disease is associated with anorectic agents, such as fenfluramine, and antimigraine medications, such as ergot-amine, via serotonin 5-HT2B receptor agonism66.”
From Unexplored therapeutic opportunities in the human genome (2018) · cites this paper as [66]
Citations
Cites
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 884
Rothman, R. B., Baumann, M. H., Savage, J. E., Rauser, L., McBride, A., Hufeisen, S. J., & Roth, B. L. (2000) · Circulation · doi:10.1161/01.cir.102.23.2836 · Cited by 722
Self-citationDopamine Agonists and the Risk of Cardiac-Valve Regurgitation
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 718
Setola, V., Hufeisen, S. J., Grande-Allen, K. J., Vesely, I., Glennon, R. A., Blough, B., Rothman, R. B., & Roth, B. L. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.6.1223 · Cited by 304
Self-citationAppetite Suppressants and Valvular Heart Disease
Devereux, R. B. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809103391109 · Cited by 53
Setola, V., & Roth, B. L. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.3.377 · Cited by 48
Self-citation
Cited by
Items 101–200 of 503
Duan, W., Cao, D., Wang, S., & Cheng, J. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00375 · Cited by 85
Engineered GPCRs as Tools to Modulate Signal Transduction
Pei, Y., Rogan, S. C., Yan, F., & Roth, B. L. (2008) · Physiology · doi:10.1152/physiol.00025.2008 · Cited by 76
Self-citationCardiac and noncardiac fibrotic reactions caused by ergot‐and nonergot‐derived dopamine agonists
Andersohn, F., & Garbe, E. (2008) · Movement Disorders · doi:10.1002/mds.22385 · Cited by 75
Svejda, B., Kidd, M. S., Giovinazzo, F., Eltawil, K. M., Gustafsson, B. I., Pfragner, R., & Modlin, I. M. (2010) · Cancer · doi:10.1002/cncr.25049 · Cited by 80
“dexfenfluramine, pergolide, cabergoline, ergotamine) are associated with pulmonary fibrosis and valvular heart disease.(13,14) Considerable evidence, therefore, exists that 5HT2B receptors are involved in cellular pathways that culminate in fibrosis.”
BackgroundKennett, G. A., & Clifton, P. G. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.07.020 · Cited by 83
Crystal structure of the human 5-HT1B serotonin receptor bound to an inverse agonist
Yin, W., Zhou, X. E., Yang, D., de Waal, P. W., Wang, M., Dai, A., Cai, X., Huang, C., Liu, P., Wang, X., et al. (2018) · Cell Discovery · doi:10.1038/s41421-018-0009-2 · Cited by 81
Lin, X., Huang, X.-P., Chen, G., Whaley, R., Peng, S., Wang, Y., Zhang, G., Wang, S. X., Wang, S., Roth, B. L., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300338m · Cited by 73
Self-citationValvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals
Dahl, C. F., Allen, M. R., Urie, P. M., & Hopkins, P. N. (2008) · BMC Medicine · doi:10.1186/1741-7015-6-34 · Cited by 73
“Recent evidence seems to confirm the suspicion that excessive stimulation of the serotonin or 5-hydroxytryptamine (5-HT) 2B receptor results in valvular damage and regurgitation [16-18].”
Domínguez‐Soto, Á., Usategui, A., Casas-Engel, M. D. L., Simón‐Fuentes, M., Nieto, C., Cuevas, V. D., Vega, M. A., Pablos, J. L., & Corbí, A. L. (2017) · Scientific Reports · doi:10.1038/s41598-017-15348-y · Cited by 76
Eshleman, A. J., Wolfrum, K. M., Reed, J. F., Kim, S. O., Johnson, R. A., & Janowsky, A. J. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.024 · Cited by 79
“In addition, although these compounds had high affinity for the 5-HT2B receptor, they had 11–146 times lower potencies at activating 5-HT2B compared to 5-HT2A receptors, and only partial efficacy, which suggests that they could cause cardiac valvulopathy only with chronic and high dose use [28].”
Cozzi, R. C., Ambrosio, M. R., Attanasio, R., Battista, C., Bozzao, A., Caputo, M., CICCARELLI, E., Marinis, L. D., Menis, E. D., Fustini, M. F., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-0977 · Cited by 77
Melmed, S. K. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1409 · Cited by 73
“The authors also assessed sporting type, ethnicity, body mass index, gender, and age as determinants of the GH axis, including IGF-I, IGF binding protein-3, FIG. 2. 5-HT2B agonists ( 24 ).”
BackgroundHassan, S. A., Banchs, J. A., Iliescu, C., Dasari, A. N., Lopez‐Mattei, J., & Yusuf, S. W. (2017) · Heart · doi:10.1136/heartjnl-2017-311261 · Cited by 70
New therapeutic opportunities for 5-HT2 receptor ligands
Maroteaux, L., Ayme‐Dietrich, E., Aubertin-Kirch, G., Banas, S. M., Quentin, E., Lawson, R., & Monassier, L. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.10.008 · Cited by 66
Kuhn, E., & Chanson, P. (2016) · Pituitary · doi:10.1007/s11102-016-0782-6 · Cited by 73
“Stimulation of these receptors activates several mitogenic pathways, ultimately causing valve overgrowth [64].”
BackgroundDual dopamine/serotonin releasers: Potential treatment agents for stimulant addiction.
Rothman, R. B., Blough, B. E., & Baumann, M. H. (2008) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0014103 · Cited by 71
“Of note, accumulating data support this hypothesis (Fitzgerald et al., 2000; Porter et al., 1999; Roth, 2007; Setola & Roth, 2005).”
BackgroundResultThe serotonin 5-HT2Creceptor and the non-addictive nature of classic hallucinogens
Canal, C. E., & Murnane, K. S. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881116677104 · Cited by 67
“Moreover, as prolonged activation of 5-HT2B receptors on heart valve leaflets is linked to valvular heart disease (Hutcheson et al., 2012; Roth, 2007; Rothman and Baumann, 2009), an impetus to develop highly-selective 5-HT2B agonists has been lacking.”
Shape Signatures: New Descriptors for Predicting Cardiotoxicity In Silico
Chekmarev, D. S., Kholodovych, V., Balakin, K. V., Ivanenkov, Y., Ekins, S., & Welsh, W. J. (2008) · Chemical Research in Toxicology · doi:10.1021/tx800063r · Cited by 66
Review Paper: Current Strategies in the Development of Anti-obesity Drugs and Their Safety Concerns
Elangbam, C. S. (2009) · Veterinary Pathology · doi:10.1354/vp.46-1-10 · Cited by 66
The polypharmacology of psychedelics reveals multiple targets for potential therapeutics
Jain, M. K., Gumpper, R. H., Slocum, S. T., Schmitz, G. P., Madsen, J. S., Tummino, T. A., Suomivuori, C., Huang, X.-P., Shub, L., DiBerto, J. F., et al. (2025) · Neuron · doi:10.1016/j.neuron.2025.06.012 · Cited by 89
Self-citationRoth, B. L. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.012 · Cited by 73
“…serotonin receptors (Roth et al., 1998), have emerged as important potential therapeutic targets for antipsychotic, antidepressant, anorectic, anti-insomnia, cardiovascular and anxiolytic medications (Kozikwski et al.,; Roth et al., 2004; Roth, 2007; Berger et al., 2009; Cho et al., 2009).”
BackgroundSelf-citationEtiology of OHSS and use of dopamine agonists
Soares, S. R. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.12.046 · Cited by 65
Hyperprolactinemia and prolactinoma
Romijn, J. A. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-59602-4.00013-7 · Cited by 73
Appetite Suppressants, Cardiac Valve Disease and Combination Pharmacotherapy
Rothman, R. B., & Baumann, M. H. (2009) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31817fde95 · Cited by 64
Busso, C., Sánchez, M. F., García-Velasco, J. A., Landeras, J. J., Ballesteros, Á., Munoz, E., Gonzalez, S., Simón, C., Arce, J., & Pellicer, A. (2010) · Human Reproduction · doi:10.1093/humrep/deq005 · Cited by 64
“Human Reproduction, Vol.25, No.4 pp. 995–1004, 2010 Advanced Access publication on February 6, 2010 doi:10.1093/humrep/deq005”
BackgroundInfluentialWeissman, N. J., Sanchez, M., Koch, G. G., Smith, S. R., Shanahan, W. R., & Anderson, C. M. (2013) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.112.000128 · Cited by 70
“Lorcaserin was designed to stimulate the 5-HT 2C receptor without activating the 5-HT 2B receptor at therapeutic doses, thereby minimizing the risk of valvular heart disease.(7,9,11) The phase 3 safety and efficacy studies of lorcaserin included a comprehensive echocardiographic monitoring program that evaluated the p…”
MethodDelgado, V., Biermasz, N. R., van Thiel, S. W., Ewe, S. H., Marsan, N. A., Holman, E. R., Feelders, R. A., Smit, J. W. A., Bax, J. J., & Pereira, A. M. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04326.x · Cited by 63
Conway, S. J., Doetschman, T., & Azhar, M. (2011) · The Scientific World JOURNAL · doi:10.1100/tsw.2011.132 · Cited by 69
“, pergolide and cabergoline) valvular disease[14,15,16,17,18,19,20].”
BackgroundMolecular mechanisms underlying the onset of degenerative aortic valve disease
Hakuno, D., Kimura, N., Yoshioka, M., & Fukuda, K. (2008) · Journal of Molecular Medicine · doi:10.1007/s00109-008-0400-9 · Cited by 66
“For these reasons, some investigators [60] have raised the possibility that the ergot dopamine agonists activate 5-HT(2B) signaling pathway through Gαq, ERK1/2, Src, and protein kinase C, leading to hyperplasia of valvular interstitial cells, valve degeneration, and eventually, regurgitation.”
Background10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas
Andereggen, L., Frey, J., Andres, R. H., El‐Koussy, M., Beck, J., Seiler, R. W., & Christ, E. (2016) · Endocrine · doi:10.1007/s12020-016-1115-2 · Cited by 65
2-Phenethylamines in Medicinal Chemistry: A Review
Nieto, C. T., Manchado, A., Belda, L., Diez, D., & Garrido, N. M. (2023) · Molecules · doi:10.3390/molecules28020855 · Cited by 67
Approving the Vagus-Nerve Stimulator for Depression
Shuchman, M. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078035 · Cited by 60
Tan, T., Cabrita, I. Z., Moss, D. J. H., Grogono, J. C., Dhillo, W. S., Baynes, K., Eliahoo, J., Meeran, K. M., Robinson, S., Nihoyannopoulos, P., et al. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03827.x · Cited by 59
A chemogenomic approach to drug discovery: focus on cardiovascular diseases
Cases, M., & Mestres, J. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.02.010 · Cited by 63
Boguszewski, C. L., Santos, C., Sakamoto, K. S., Marini, L. C., de Souza, A. M., & Azevedo, M. F. (2011) · Pituitary · doi:10.1007/s11102-011-0339-7 · Cited by 59
“Compared to CBG, BRC shows weaker affinity for the 5-HT2B receptors and, therefore, is thought to be less valvulopathic [6, 7].”
BackgroundPharmacotherapy of neuroendocrine cancers
Modlin, I., Kidd, M. S., Drozdov, I. A., Siddique, Z.-L., & Gustafsson, B. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.15.2617 · Cited by 59
“Additionally, fenfluramine, a serotonergic agonist used as an appetite suppressant, induces cardiac valvular heart disease similar to that evident in the carcinoid syndrome [110] .”
BackgroundAdverse effects of medications commonly used in the treatment of migraine
Whyte, C. A., & Tepper, S. J. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.47 · Cited by 61
Nieto, C., Rayo, I., Casas-Engel, M. D. L., Izquierdo, E., Alonso, B., Béchade, C., Maroteaux, L., Vega, M. A., & Corbí, A. L. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1901531 · Cited by 61
“potent off-target effects on 5-HT2B (36).”
Secondary pharmacology: screening and interpretation of off-target activities – focus on translation
Whitebread, S., Dumotier, B. M., Armstrong, D., Fekete, A., Chen, S., Hartmann, A., Muller, P. Y., & Urbán, L. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.021 · Cited by 61
A serotonin-induced N-glycan switch regulates platelet aggregation
Mercado, C. P., Quintero, M. V., Li, Y., Singh, P., Byrd, A. K., Talabnin, K., Ishihara, M., Azadi, P., Rusch, N. J., Kuberan, B., et al. (2013) · Scientific Reports · doi:10.1038/srep02795 · Cited by 56
Serotonin produces monoamine oxidase-dependent oxidative stress in human heart valves
Silva, R. A. P., Miller, J. D., Chu, Y., & Heistad, D. D. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00570.2009 · Cited by 58
Pharmacology of MDMA- and Amphetamine-Like New Psychoactive Substances
Simmler, L. D., & Liechti, M. E. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_113 · Cited by 65
Nachtigall, L. B., Valassi, E., Lo, J., McCarty, D., Passeri, J. J., Biller, B. M. K., Miller, K. K., Utz, A. L., Grinspoon, S. K., Lawson, E. A., et al. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03608.x · Cited by 57
Simonis, G., Fuhrmann, J. T., & Strasser, R. H. (2007) · Movement Disorders · doi:10.1002/mds.21639 · Cited by 55
Psychedelics as Transformative Therapeutics
Roth, B. L., & Gumpper, R. H. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230172 · Cited by 58
Self-citationCho, S. J., Jensen, N., Kurome, T., Kadari, S., Manzano, M. L., Malberg, J. E., Caldarone, B. J., Roth, B. L., & Kozikowski, A. P. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801354e · Cited by 63
Self-citationCardiac Changes in Parkinson’s Disease: Lessons from Clinical and Experimental Evidence
Cuenca‐Bermejo, L., Almela, P., Zaragoza, J. N., Fernández‐Villalba, E., Cuello, A. M. G., Laorden, M. L., & Herrero, M. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413488 · Cited by 68
Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline
Lafeber, M., Stades, A. M. E., Valk, G. D., Cramer, M. J., van Berkhout, F. T., & ZELISSEN, P. M. J. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0989 · Cited by 53
Large-Scale Predictive Drug Safety: From Structural Alerts to Biological Mechanisms
García-Serna, R., Vidal, D., Remez, N., & Mestres, J. (2015) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00260 · Cited by 56
Zebrafish studies identify serotonin receptors mediating antiepileptic activity in Dravet syndrome
Griffin, A., Jaishankar, P., Grandjean, J.-M. M., Olson, S. H., Renslo, A. R., & Baraban, S. C. (2019) · Brain Communications · doi:10.1093/braincomms/fcz008 · Cited by 56
“Indeed, activation of 5-HT2BR can induce a mitogenic effect on valvular endothelial cells and has resulted in the discontinued development of some compounds (Roth, 2007).”
BackgroundBromocriptine use and the risk of valvular heart disease
Tan, L. C. S., Ng, K. K. C., Au, W., Lee, R. K. K., Chan, Y., & Tan, N. C. (2008) · Movement Disorders · doi:10.1002/mds.22228 · Cited by 54
“bromocriptine is a safe drug that is not associated with valvular heart disease.(3,4)”
BackgroundFenfluramine Disrupts the Mitral Valve Interstitial Cell Response to Serotonin
Connolly, J. M., Bakay, M. A., Fulmer, J. T., Gorman, R. C., Gorman, J. H., Oyama, M. A., & Levy, R. J. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.081101 · Cited by 58
Serotonin 2B Receptor Antagonism Prevents Heritable Pulmonary Arterial Hypertension
West, J. D., Carrier, E. J., Bloodworth, N. C., Roest, A. S. V., Chen, P., Ryzhova, L., Gladson, S., Shay, S. D., Hutcheson, J. D., & Merryman, W. D. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148657 · Cited by 59
“Likewise, agonism of HTR2B, by either serotonin or metabolites from anorexigens, does the same [16,17].”
Background2012 update in the treatment of prolactinomas
Maiter, D. M., & Primeau, V. (2012) · Annales d Endocrinologie · doi:10.1016/j.ando.2012.03.024 · Cited by 51
Enkhmaa, B., Surampudi, P. N., Anuurad, E., & Berglund, L. (2015) · Europe PMC (PubMed Central) · Cited by 65
NEURAL AND CARDIAC TOXICITIES ASSOCIATED WITH 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA)
Baumann, M., & Rothman, R. (2009) · International review of neurobiology · doi:10.1016/s0074-7742(09)88010-0 · Cited by 46
“Both of these medications are known to increase the risk of VHD (for review see Roth, 2007).”
BackgroundDrug-induced valvular heart disease
Cosyns, B., Droogmans, S., Rosenhek, R., & Lancellotti, P. (2012) · Heart · doi:10.1136/heartjnl-2012-302239 · Cited by 54
Anticipating drug side effects by comparative pharmacology
García-Serna, R., & Mestres, J. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.509343 · Cited by 54
“For example, blockade of the hERG potassium channel may result in QT interval prolongation [11] or agonism for the serotonin 5-HT2B receptor may translate into the possible occurrence of cardiac valvulopathy [12].”
BackgroundSafety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications
Halpern, B., & Halpern, A. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.994502 · Cited by 51
“The adverse effect, which led to its discontinuation, arose from it being a selective 5HT2B agonist [78,80,83].”
BackgroundRecommandations pratiques de prise en charge de la drépanocytose de l’adulte
Lionnet, F., Arlet, J. B., Bartolucci, P., Habibi, A., Ribeil, J., & Stankovic, K. (2009) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2009.07.001 · Cited by 54
Hajjo, R., Grulke, C., Golbraikh, A., Setola, V., Huang, X., Roth, B. L., & Tropsha, A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100600y · Cited by 51
Self-citationThe Cabergoline-Resistant Prolactinoma Patient: New Challenges
Molitch, M. E. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2244 · Cited by 48
Zhang, B., Zhao, S., Yang, D., Wu, Y., Ye, X., Cao, H., Huang, X., Cai, X., Sun, W. C., Ye, N., et al. (2020) · ACS Central Science · doi:10.1021/acscentsci.9b01125 · Cited by 51
In Vitro Safety Pharmacology Profiling: What Else Beyond Herg?
Hamon, J., Whitebread, S., Techer-Etienne, V., Coq, H. L., Azzaoui, K., & Urbán, L. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.51 · Cited by 51
Reduced Adverse Event Profile of Orally Inhaled DHE (MAP0004) vs IV DHE: Potential Mechanism
Cook, R. O., Shrewsbury, S. B., & Ramadan, N. M. (2009) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2009.01510.x · Cited by 47
“Agonist action at 5-HT2B receptors has been implicated as a cause for cardiac valvulopathy with ergot alkaloid-type drugs used for Parkinson’s disease.(29) Thus, potential cardiovascular selectivity exists for MAP0004 vs IV DHE based on differences in functional agonism at the 5-HT2B receptor subtype.”
BackgroundQuantum Chemistry Simulation of Biological Molecules
Albuquerque, E. L., Fulco, U. L., Caetano, E. W. S., & Freire, V. N. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108774956 · Cited by 54
Chemogenetics—A Transformational and Translational Platform
English, J. G., & Roth, B. L. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1921 · Cited by 44
Self-citationJebadurai, J. K. (2013) · University of Hertfordshire Research Archive (University of Hertfordshire) · doi:10.18745/th.11352 · Cited by 45
Smith, S. A., Waggoner, A. D., Fuentes, L. D. L., & Dávila‐Román, V. G. (2009) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2009.05.002 · Cited by 44
“(39) Up-regulation of TGFB has been shown to lead to increased extracellular matrix, including collagen and glycosaminoglycans in human aortic valve interstitial cells, potentially playing a significant role in increasing fibrosis and subsequent valvulopathy.”
BackgroundRevisiting the Role of Ergots in the Treatment of Migraine and Headache
Baron, E. P., & Tepper, S. J. (2010) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2010.01662.x · Cited by 43
“The mechanism for fibrotic complications appears linked to 5-HT2B agonism.(22) 1356 September 2010”
BackgroundEstimate of deaths due to valvular insufficiency attributable to the use of benfluorex in France
Fournier, A., & Zureik, M. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3213 · Cited by 43
Tran, T., Brophy, J. M., Suissa, S., & Renoux, C. (2015) · CNS Drugs · doi:10.1007/s40263-015-0293-4 · Cited by 48
“Stimulation of 5-HT2B receptors induces proliferation of fibroblasts within valve tissue, which leads to valvular damage [34, 36].”
BackgroundDevin, J. K., Lakhani, V. T., Byrd, B. F., & Blevins, L. S. (2008) · Endocrine Practice · doi:10.4158/ep.14.6.672 · Cited by 43
Fish, P. V., Brown, A. D., Evrard, E., & Roberts, L. R. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.02.071 · Cited by 42
Halpern, B., & Mancini, M. C. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1247807 · Cited by 41
“tive serotoninergic agonism of fenfluramine [23,24].”
BackgroundTargeting the 5-HT system: Potential side effects
Hoyer, D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108233 · Cited by 45
Dopamine/serotonin releasers as medications for stimulant addictions
Rothman, R. B., Blough, B. E., & Baumann, M. H. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00919-9 · Cited by 47
“ed in Rothman et al. (2007).”
ResultInfluentialStummann, T. C., Beilmann, M., Duker, G., Dumotier, B. M., Fredriksson, J. M., Jones, R. L., Hasiwa, M., Kang, Y. J., Mandenius, C., Meyer, T. S., et al. (2009) · Cardiovascular Toxicology · doi:10.1007/s12012-009-9045-3 · Cited by 41
“Over the last decade it has become well established that agonists of the 5-HT2B (5-hydroxytryptamine) receptor can cause valvular heart disease [20].”
BackgroundZopf, D. A., Neves, L. A. A., Nikula, K. J., Huang, J., Senese, P. B., & Gralinski, M. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.08.015 · Cited by 47
“, 2002), a negative outcome that is mirrored in patients who ingest 5-HTR2B agonists (Roth, 2007), many of which have been withdrawn from the market because of increased risk of both proliferative cardiac valvulopathies and PAH (Rothman et al.”
BackgroundPolster, T. (2018) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2018.08.021 · Cited by 44
“The same type of cardiac morbidity can be seen in patients with carcinoid tumors, suggesting a relevant role of high serotonin levels, which have been shown to interact via the 5HT2B-receptor [27].”
An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: Emerging ‘Novel Psychoactive Drugs’
Arunotayanun, W., Dalley, J. W., Huang, X., Setola, V., Treble, R., Iversen, L. L., Roth, B. L., & Gibbons, S. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.03.066 · Cited by 40
Self-citationLorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease
Bays, H. E. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.123 · Cited by 39
Cabergoline use and risk of fibrosis and insufficiency of cardiac valves
Vecchis, R. D., Esposito, C., & Ariano, C. (2013) · Herz · doi:10.1007/s00059-013-3816-0 · Cited by 39
Storer, R. I., Brennan, P. E., Brown, A. D., Bungay, P. J., Conlon, K. M., Corbett, M. S., DePianta, R. P., Fish, P. V., Heifetz, A., Ho, D. K. H., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5003292 · Cited by 40
Perrine, S. A., Michaels, M. S., Ghoddoussi, F., Hyde, E., Tancer, M. E., & Galloway, M. P. (2008) · NMR in Biomedicine · doi:10.1002/nbm.1352 · Cited by 43
“MDMA causes fenfluramine-like proliferation of valvular interstitial cells in vitro (18) by a mechanism that involves 5HT2B receptors (19).”
BackgroundCorvol, J., Anzouan-Kacou, J.-B., Fauveau, É., Bonnet, A.-M., Lebrun‐Vignes, B., Girault, C., Agid, Y., Lechat, P. P., Isnard, R., & Lacomblez, L. (2007) · Archives of Neurology · doi:10.1001/archneur.64.12.1721 · Cited by 41
“Because fenfluramine metabolite is a potent serotonin receptor agonist, pergolide valvulopathies have been postulated to be related to a serotoninergic mechanism.(23) Fenfluramine and pergolide, as well as cabergoline, share agonist properties with serotonin 2 receptors.”
BackgroundJebadurai, J. K., Schifano, F., & Deluca, P. (2013) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2302 · Cited by 43
Tribouilloy, C. M., Ruşinaru, D., Maréchaux, S., Jeu, A., Éderhy, S., Donal, E., Réant, P., Arnalsteen, E., Boulanger, J., Ennezat, P., et al. (2012) · Circulation · doi:10.1161/circulationaha.112.111260 · Cited by 38
“The molecular mechanism is a G-protein–mediated upregulation of transforming growth factor- that stimulates mitogenic pathways and leads to increased production of glycosaminoglycans and collagen.(21,22) The risk of heart valve disease associated with exposure to benfluorex was acknowledged after the recent publicatio…”
BackgroundDesign and Discovery of Functionally Selective Serotonin 2C (5-HT2C) Receptor Agonists
Cheng, J., McCorvy, J. D., Giguère, P. M., Zhu, H., Kenakin, T., Roth, B. L., & Kozikowski, A. P. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01194 · Cited by 42
Self-citationInflammatory Regulation of Valvular Remodeling: The Good(?), the Bad, and the Ugly
Mahler, G. J., & Butcher, J. T. (2011) · International Journal of Inflammation · doi:10.4061/2011/721419 · Cited by 52
Martí-Solano, M., Sanz, F., Pastor, M., & Selent, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109312 · Cited by 36
“Understanding selectivity at these receptors is of special interest as agonism at the 5-HT1BR has been associated to the anti-migraine effect of ergotamine while agonism at the 5-HT2BR seems to be related to undesired valvulopathic effects [11,12].”
BackgroundNo clinically significant valvular regurgitation in long‐term cabergoline treatment for prolactinoma
Halperín, I., Aller, J., Varela, C., Mora, M., Abad, A. Z., Doltra, A., Santos, A. E., Batista, E., García‐Pavía, P., Sitges, M., et al. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04349.x · Cited by 38
Ven, F. L., Tribouilloy, C., Habib, G., Gueffet, J.-P., Maréchaux, S., Eicher, J., Blanchard-Lemoine, B., Rousseau, J., Henon, P., Jobic, Y., et al. (2010) · European Journal of Echocardiography · doi:10.1093/ejechocard/jeq172 · Cited by 37
Safety and tolerability review of lorcaserin in clinical trials
Greenway, F. L., Shanahan, W. R., Fain, R., Ma, T., & Rubino, D. (2016) · Clinical Obesity · doi:10.1111/cob.12159 · Cited by 39
“Adverse effects that could be theoretically associated with known activities of the 5-HT2 family of receptors in animals and/or humans include alterations in perception (2A) (21), cardiac valvular insufficiency (2B) (43), serotonin syndrome (2A and possibly 2C) (32,33), prolactin release (2A/2C) (44,45), and penile ex…”
BackgroundModern Obesity Pharmacotherapy: Weighing Cardiovascular Risk and Benefit
Cunningham, J. W., & Wiviott, S. D. (2014) · Clinical Cardiology · doi:10.1002/clc.22304 · Cited by 37
Droogmans, S., Roosens, B., Cosyns, B., Degaillier, C., Hernot, S., Weytjens, C., Garbar, C., Caveliers, V., Pipeleers-Marichal, M. A., Franken, P. R., et al. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01177.2008 · Cited by 37
“4 nM) (33) and was therefore recently proposed by Roth (24) as a theoretical candidate for the prevention of drug-induced valvular heart disease.”
BackgroundResultInfluentialLacerda, C. M. R., Kisiday, J. D., Johnson, B., & Orton, E. C. (2012) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00987.2011 · Cited by 36
Khan, M. N. A., Suzuki, T., & Miyata, N. (2012) · Medicinal Research Reviews · doi:10.1002/med.21269 · Cited by 35
Biosynthesis, total synthesis, and biological profiles of Ergot alkaloids
Tasker, N. R., & Wipf, P. (2020) · The Alkaloids. Chemistry and biology/The alkaloids. Chemistry and biology · doi:10.1016/bs.alkal.2020.08.001 · Cited by 48
Surgical treatment of microprolactinomas: pros
Salvatori, R. (2014) · Endocrine · doi:10.1007/s12020-014-0281-3 · Cited by 33
Metadata
- Authors
- Roth, B. L.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Roth, Bryan L.
- ORCID
- Roth, Bryan L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-01-04
- Volume
- 356
- Issue
- 1
- Pages
- 6-9
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1965258805
- Cited by
- 479
- References
- 7
- Citations by year
- 2026: 10 · 2025: 9 · 2024: 11 · 2023: 14 · 2022: 20 · 2021: 18 · 2020: 17 · 2019: 18 · 2018: 20 · 2017: 19 · 2016: 30 · 2015: 29 · 2014: 25 · 2013: 32 · 2012: 28
- FWCI
- 35.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Keywords
- fenfluramine, dexfenfluramine, valvular heart disease, drug-induced valvular disease, leaflet thickening, echocardiographic findings
- MeSH terms
- Cabergoline, Antiparkinson Agents, Ergolines, Heart Valve Diseases, Humans, Pergolide, Serotonin Receptor Agonists, Dopamine Agonists, Receptor, Serotonin, 5-HT2B, Serotonin 5-HT2 Receptor Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.